VCYT News and Press, Veracyte Inc. From 05/03/23

2023-05-03 17:35:59 ET Veracyte ( NASDAQ: VCYT ) is scheduled to announce Q1 earnings results on Thursday, May 4th, after market close. The consensus EPS Estimate is -$0.11 (+45.0% Y/Y) and the consensus Revenue Estimate is $75.75M (+11.8% Y/Y). Over the last 1 year, V...

Veracyte, Inc. (Nasdaq: VCYT) today announced that it released its inaugural Environmental, Social and Governance (ESG) Report . The 2023 ESG Report sets the foundation for Veracyte’s ESG performance and outlines the company’s ambitions to build upon its progress in the years ...

Findings represent first validation of any gene expression biomarker for intermediate-risk patients using data from a randomized phase 3 clinical trial Veracyte, Inc . (Nasdaq: VCYT) announced that data published in the International Journal of Radiation Oncology, Biology, Physi...

Veracyte, Inc. (Nasdaq: VCYT) today announced that three abstracts focused on the company’s genomic tests for interstitial lung disease (Envisia Genomic Classifier) and lung cancer (Percepta Nasal Swab) will be presented at the American Thoracic Society (ATS) 2023 International Conferenc...

Data from studies encompassing over 100,000 prostate cancer patients presented at American Urology Association (AUA) 2023 Annual Meeting Veracyte, Inc . (Nasdaq: VCYT) announced that new data presented at the American Urological Association (AUA) 2023 Annual Meeting validate the...

Veracyte, Inc. (Nasdaq: VCYT) today announced that five abstracts providing new molecular insights into prostate and other cancers will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago and online June 2-6. Three of the accepted abstra...

Findings published in European Urology Oncology suggest genomic classifier scores are highly correlated with PSMA PET upstaging of prostate cancer in those with high-risk and very high-risk disease Veracyte, Inc . (Nasdaq: VCYT) announced that new data published in European ...

Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2023 after the close of market on Thursday, May 4, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business update at...

Accepted abstracts include three summarizing findings from separate, large-scale, real-world studies evaluating clinical utility of Decipher Prostate Genomic Classifier Veracyte, Inc . (Nasdaq: VCYT) announced today that seven abstracts highlighting new data from studies of the comp...

2023-03-17 16:16:22 ET Summary Here's a long list of biopharmas exposed to SVB Financial Group. Many of these deposits will be uninsured. However, since SVB Financial Group was quite solvent otherwise, much of these deposits should be recoverable by these small companies. ...